North American Myocardial Infarction Market 2020-2026

North American Myocardial Infarction Market Size, Share & Trends Analysis Report by Type (ST-Elevation Myocardial Infarction (STEMI), Non-ST Elevation Myocardial Infarction (NSTEMI), and Silent Heart Attacks), by Device (Left Ventricular Assist Device, Pacemaker, Catheter, Implantable Cardioverter Defibrillator, and Others), by Diagnosis (Electrocardiography (ECG), Chest X-Ray, Computed Tomography (CT Scan), Echocardiography, and Others), by Treatment (Medication and Surgery), and by End-Users (Hospitals & Clinics, Ambulatory Surgical Centers, and Research Institutes) and Forecast, 2020-2026.

North American myocardial infarction market is estimated to grow significantly at a CAGR of around 6.6% during the forecast period. North America contributes the highest share in the global myocardial infarction treatment market owing to the highest adoption devices and surgeries that are required for the treatment of MI. In the US alone, around 0.6 million people lose their life due to heart diseases, according to the WHO, the incidence & prevalence rate of heart attack are the highest in North America which is responsible for 0.7 million fatalities each year. According to the Heart & Stroke Foundation, in Canada alone, 1.6 million fatalities occur every year due to stroke and at least 1.3 million Canadians live with heart disease. Moreover, the growing CVD, CHD, stroke and other heart diseases, highest healthcare spending, technological advancement and adoption of hybrid operating rooms and minimally invasive surgeries are the key drivers of the MI treatment market in the region.

The market is segmented into type, device, diagnosis, treatment, and end-user. Based on type, the market is segmented into ST-elevation myocardial infarction (STEMI) heart attacks, non-ST elevation myocardial infarction (NSTEMI) heart attacks, and silent heart attacks. Based on the device, the market is segmented into left ventricular assist device, pacemaker, implantable cardioverter defibrillator, and others (aspiration-based catheters). Based on the diagnosis, the market is segmented into an electrocardiography (ECG), chest X-Ray, Computed Tomography (CT Scan), echocardiography, and others (blood test). Based on treatment, the market is segmented into medication and surgery. Based on end-user, the market is segmented into hospitals & clinics, Ambulatory Surgical Centers (ASCs), and research institutes.

The companies which are contributing to the growth of the North American myocardial infarction market include Abbott Laboratories Inc., Johnson & Johnson Services Inc., Mylan N.V., Pfizer Inc., Bayer AG, and Novartis AG. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market. For instance, in June 2019, Abbott Laboratories Inc. acquired St. Jude Medical, a medical device provider. This acquisition was aimed to take leverage of St. Jude's product portfolio that includes Ellipse VR, Ellipse Dual-Chamber ICD, Accent SR RF, Accent RF, and many other devices. Additionally, this acquisition was aimed to complement Abbott Laboratories Inc.’s cardiovascular business segment.

Research Methodology

The market study of the North American myocardial infarction market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook.

In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.

Secondary Sources Include

• Financial reports of companies involved in the market.
• Whitepapers, research-papers, and news blogs.
• Company websites and their product catalog.

The report provides an in-depth analysis of market size, various services offered by the players, and market opportunity. The report will serve as a source for 360-degree analysis of the market delivering insights for making better business decisions.

Market Segmentation

1. North American Myocardial Infarction Market Research and Analysis by Type
2. North American Myocardial Infarction Market Research and Analysis by Device
3. North American Myocardial Infarction Market Research and Analysis by Diagnosis
4. North American Myocardial Infarction Market Research and Analysis by Treatment
5. North American Myocardial Infarction Market Research and Analysis by End-Users

The Report Covers

• Comprehensive research methodology of the North American myocardial infarction market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the North American myocardial infarction market.
• Insights about market determinants which are stimulating the North American myocardial infarction market.
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.